General Archives - Gilde Healthcare

Neuigkeiten
& Einblicke

Gilde Healthcare strengthens US Venture&Growth team with Rich Wilmot as partner

Gilde Healthcare, a leading transatlantic investment firm specialized in the healthcare sector, today announced the appointment of Rich Wilmot as a Partner in its US Venture&Growth team. Mr. Wilmot brings over 15 years of experience in digital health and healthtech investing to the firm. Wilmot's appointment comes at an exciting time as Gilde Healthcare continues to expand its presence in...
8. Juni 2023

Gilde Healthcare legt sechsten Venture & Growth Fonds mit einem Volumen von 600 Millionen EUR für Investitionen in Europa und Nordamerika auf

test Ein ausgewogener Mix internationaler Investoren stellt 600 Millionen Euro für den transatlantisch investierenden Gilde Healthcare Venture&Growth VI zur Verfügung Gilde Healthcare investiert in schnell wachsende Unternehmen, die eine verbesserte Gesundheitsversorgung bei gleichzeitig geringeren Kosten zum Ziel haben. Dabei wird Gilde von seinem unlängst ernannten Impact Council unterstützt Innerhalb von drei Jahren hat Gilde Healthcare über […]

Gilde Healthcare portfolio company Moximed obtains FDA Market Authorization of the MISHA™ Knee System for People Suffering from Knee Osteoarthritis

test Implantable shock absorber (ISA) relieves pain and improves function in people ineligible for, or unwilling to undergo, joint replacement MISHA Knee System is implanted during an outpatient procedure; it’s the first and only device of its kind for people with symptomatic knee OA  More than 32 million people in the United States are affected by […]

Gilde Healthcare company Adcendo announces extension of series A financing to EUR 82M to develop its first-in-class ADC pipeline

Gilde Healthcare portfolio company Adcendo Aps (‘Adcendo’), focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, today announces the successful completion of a Series A extension financing, raising a further EUR 31M, following the EUR 51M...

GT Medical Technologies Raises $45 Million in Oversubscribed Series C Financing Led by Gilde Healthcare

GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, announced that it has raised $45 million in a Series C financing led by Gilde Healthcare Partners with participation from existing institutional investors MVM Partners, MedTech Venture Partners, and...

Gilde Healthcare company FIRE1 raises $25 million to revolutionize heart failure home monitoring

Gilde Healthcare company FIRE1 today announced the close of a $25 million financing round led by new investors Andera Partners and Novo Holdings, with participation and ongoing support from existing investors Gilde Healthcare, Gimv, the Ireland Strategic Investment Fund, Lightstone Ventures, Medtronic, New Enterprise Associates and Seventure Partners. The financing provides FIRE1 with capital to accelerate the development of its novel remote monitoring solution to improve...

Gilde Healthcare company Noema Pharma raises CHF 103 million ($112 million)

Gilde Healthcare, a leading specialized healthcare investor, today announced that its portfolio company Noema Pharma, has raised an oversubscribed CHF 103 million ($112 million) Series B financing round from new and existing investors. Noema Pharma is a clinical-stage biopharma company targeting debilitating central nervous system (CNS) disorders....

Gilde Healthcare leads $42 million growth financing round in medtech company Shoulder Innovations

Shoulder Innovations Inc. (SI), a Grand Rapids, Michigan based leader in the shoulder replacement implant market, announced closing on an oversubscribed $42 million Series D financing. SI is a commercial stage medical device company with an experienced team of successful innovators in the shoulder space. The financing was...

Gilde Healthcare company Synexa Life Sciences celebrates its 20th anniversary

Two decades of advancing drug development programs through specialist biomarker and bioanalytical insights Synexa Life Sciences, a specialist biomarker and bioanalysis services provider, celebrates its 20th anniversary on March the 3rd 2023. Since its inception in 2003, Synexa Life Sciences has become a trusted partner to pharmaceutical,...
Loading...
These were all messages
51f739d166